Medicine and Dentistry
Radiation Therapy
100%
Lung Cancer
83%
Non Small Cell Lung Cancer
42%
Neoplasm
34%
Pneumonia
29%
Immune Checkpoint Inhibitor
28%
Disease
25%
Malignant Neoplasm
24%
Intensity Modulated Radiation Therapy
21%
Chemoradiotherapy
21%
Stereotactic Body Radiation Therapy
19%
Immunotherapy
19%
Recurrent Disease
16%
Overall Survival
16%
Non-Small Cell Lung Cancer
16%
Surgery
13%
Prostate Cancer
13%
Progression Free Survival
13%
Radiomics
12%
Brain Metastasis
11%
Bone Metastasis
11%
Adenosquamous Carcinoma
11%
Symptom
11%
Health Care Cost
10%
Patient-Reported Outcome
10%
Thoracic Cancer
9%
Gastroesophageal Junction
9%
Metastatic Carcinoma
8%
Esophagus
8%
Systemic Therapy
8%
Cancer Radiotherapy
7%
Arm
7%
Esophagitis
7%
Pathologist
7%
Oncology
7%
Nivolumab
7%
Adverse Event
6%
Quality of Life
6%
Urinary System
6%
Radiation Oncologist
6%
Paclitaxel
6%
Radiation Oncology
6%
Immune-Related Adverse Events
6%
Epidermal Growth Factor Receptor
6%
Disease Exacerbation
6%
Lung Function
6%
Cancer Therapy
6%
Patient History of Radiotherapy
6%
Gastrointestinal Toxicity
5%
Hazard Ratio
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
46%
Immune Checkpoint Inhibitors
26%
Checkpoint Inhibitor Pneumonitis
23%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
21%
Paclitaxel
19%
Lung Cancer
17%
Microtubule-targeting Agents
16%
Cancer Cells
12%
Anticancer Activity
12%
Brain Metastases
12%
Overall Survival
12%
Neoadjuvant
11%
Cellular Growth
11%
Definitive Chemoradiation
11%
Pancreatic Adenosquamous Carcinoma
11%
Conventionally Fractionated
11%
Growth Conditions
11%
Gastroesophageal Junction Cancer
11%
High Density
11%
Chemoradiation
9%
Microtubules
9%
Risk Factors
8%
Taxanes
8%
Platinum-based Chemotherapy
7%
Tumor
7%
Low Density
7%
Treatment Resistance
7%
Prophylactic Cranial Irradiation
7%
Clinical Outcomes
7%
Local Control
7%
Immune-related Adverse Events
7%
Radiation Dose
7%
Nivolumab
7%
Pneumonitis
7%
Confidence Interval
6%
Radiotherapy
6%
Radiation Therapy
6%
Disease Progression
6%
Dosiomics
6%
Mitotic Checkpoint
6%
Intensity-modulated Radiation Therapy
6%
Hospitalization
6%
Nocodazole
6%
Definitive Radiotherapy
6%
Combined Modality Therapy
6%
Clinical Features
5%
Lung Function
5%
Taxol
5%
Spindle Assembly Checkpoint
5%
Early Identification
5%
